237 related articles for article (PubMed ID: 26802647)
1. Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells.
Seubwai W; Vaeteewoottacharn K; Kraiklang R; Umezawa K; Okada S; Wongkham S
Oncol Res; 2016 Jan; 23(1-2):21-8. PubMed ID: 26802647
[TBL] [Abstract][Full Text] [Related]
2. Thymosin β10 as a predictive biomarker of response to 5-fluorouracil chemotherapy in cholangiocarcinoma.
Sribenja S; Natthasirikul N; Vaeteewoottacharn K; Sawanyawisuth K; Wongkham C; Jearanaikoon P; Wongkham S
Ann Hepatol; 2016; 15(4):577-85. PubMed ID: 27236157
[TBL] [Abstract][Full Text] [Related]
3. Aberrant expression of NF-κB in liver fluke associated cholangiocarcinoma: implications for targeted therapy.
Seubwai W; Wongkham C; Puapairoj A; Khuntikeo N; Pugkhem A; Hahnvajanawong C; Chaiyagool J; Umezawa K; Okada S; Wongkham S
PLoS One; 2014; 9(8):e106056. PubMed ID: 25170898
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells.
Castro-Gamero AM; Borges KS; da Silva Silveira V; Lira RC; de Paula Gomes Queiroz R; Valera FC; Scrideli CA; Umezawa K; Tone LG
Anticancer Drugs; 2012 Jul; 23(6):638-50. PubMed ID: 22382389
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production.
Poma P; Notarbartolo M; Labbozzetta M; Sanguedolce R; Alaimo A; Carina V; Maurici A; Cusimano A; Cervello M; D'Alessandro N
Int J Oncol; 2006 Apr; 28(4):923-30. PubMed ID: 16525642
[TBL] [Abstract][Full Text] [Related]
6. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
[TBL] [Abstract][Full Text] [Related]
7. Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines.
Ruan HY; Masuda M; Ito A; Umezawa K; Nakashima T; Yasumatsu R; Kuratomi Y; Yamamoto T; Weinstein IB; Komune S
Head Neck; 2006 Feb; 28(2):158-65. PubMed ID: 16355386
[TBL] [Abstract][Full Text] [Related]
8. Antineoplastic Effects of NF-κB Inhibition by DHMEQ (Dehydroxymethylepoxyquinomicin) Alone and in Co-treatment with Radio-and Chemotherapy in Medulloblastoma Cell Lines.
Ramos PMM; Pezuk JA; Castro-Gamero AM; Oliveira HF; Scrideli CA; Umezawa K; Tone LG
Anticancer Agents Med Chem; 2018; 18(4):541-549. PubMed ID: 29141555
[TBL] [Abstract][Full Text] [Related]
9. Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ.
Katsman A; Umezawa K; Bonavida B
Curr Pharm Des; 2009; 15(7):792-808. PubMed ID: 19275643
[TBL] [Abstract][Full Text] [Related]
10. DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells.
Horie R; Watanabe M; Okamura T; Taira M; Shoda M; Motoji T; Utsunomiya A; Watanabe T; Higashihara M; Umezawa K
Leukemia; 2006 May; 20(5):800-6. PubMed ID: 16525497
[TBL] [Abstract][Full Text] [Related]
11. Effect of β-Eudesmol on NQO1 suppression-enhanced sensitivity of cholangiocarcinoma cells to chemotherapeutic agents.
Srijiwangsa P; Ponnikorn S; Na-Bangchang K
BMC Pharmacol Toxicol; 2018 Jun; 19(1):32. PubMed ID: 29914576
[TBL] [Abstract][Full Text] [Related]
12. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent.
Katsman A; Umezawa K; Bonavida B
Drug Resist Updat; 2007; 10(1-2):1-12. PubMed ID: 17306602
[TBL] [Abstract][Full Text] [Related]
13. Transient inhibition of NF-kappaB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation.
Dabaghmanesh N; Matsubara A; Miyake A; Nakano K; Ishida T; Katano H; Horie R; Umezawa K; Watanabe T
Cancer Sci; 2009 Apr; 100(4):737-46. PubMed ID: 19469019
[TBL] [Abstract][Full Text] [Related]
14. Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines.
Tepsiri N; Chaturat L; Sripa B; Namwat W; Wongkham S; Bhudhisawasdi V; Tassaneeyakul W
World J Gastroenterol; 2005 May; 11(18):2748-53. PubMed ID: 15884115
[TBL] [Abstract][Full Text] [Related]
15. Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells.
Meng Z; Mitsutake N; Nakashima M; Starenki D; Matsuse M; Takakura S; Namba H; Saenko V; Umezawa K; Ohtsuru A; Yamashita S
Endocrinology; 2008 Nov; 149(11):5357-65. PubMed ID: 18653704
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
Lampiasi N; Azzolina A; D'Alessandro N; Umezawa K; McCubrey JA; Montalto G; Cervello M
Mol Pharmacol; 2009 Aug; 76(2):290-300. PubMed ID: 19461054
[TBL] [Abstract][Full Text] [Related]
17. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia.
Watanabe M; Ohsugi T; Shoda M; Ishida T; Aizawa S; Maruyama-Nagai M; Utsunomiya A; Koga S; Yamada Y; Kamihira S; Okayama A; Kikuchi H; Uozumi K; Yamaguchi K; Higashihara M; Umezawa K; Watanabe T; Horie R
Blood; 2005 Oct; 106(7):2462-71. PubMed ID: 15956280
[TBL] [Abstract][Full Text] [Related]
18. Suppression of NAD(P)H-quinone oxidoreductase 1 enhanced the susceptibility of cholangiocarcinoma cells to chemotherapeutic agents.
Zeekpudsa P; Kukongviriyapan V; Senggunprai L; Sripa B; Prawan A
J Exp Clin Cancer Res; 2014 Jan; 33(1):11. PubMed ID: 24460787
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer.
Kozakai N; Kikuchi E; Hasegawa M; Suzuki E; Ide H; Miyajima A; Horiguchi Y; Nakashima J; Umezawa K; Shigematsu N; Oya M
Br J Cancer; 2012 Aug; 107(4):652-7. PubMed ID: 22805327
[TBL] [Abstract][Full Text] [Related]
20. Anoikis induction and inhibition of peritoneal metastasis of pancreatic cancer cells by a nuclear factor-κB inhibitor, (-)-DHMEQ.
Sato M; Nakanishi K; Haga S; Fujiyoshi M; Baba M; Mino K; ; Niwa H; Yokoo H; Umezawa K; Ohmiya Y; Kamiyama T; Todo S; Taketomi A; Ozaki M
Oncol Res; 2013; 21(6):333-43. PubMed ID: 25198663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]